Glenda Scandura
Overview
Explore the profile of Glenda Scandura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
204
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Claudiani S, Chughtai F, Khan A, Hayden C, Fernando F, Khorashad J, et al.
Leukemia
. 2024 Feb;
38(4):796-802.
PMID: 38424138
Second-generation tyrosine kinase inhibitors (2GTKI) are more effective in inducing rapid molecular responses than imatinib when used first-line in patients with chronic myeloid leukemia in chronic phase (CML-CP). However, failure...
2.
Scandura G, Wagner T, Beltran L, Alifrangis C, Shamash J, Berney D
Mod Pathol
. 2023 Apr;
36(4):100105.
PMID: 37084466
No abstract available.
3.
Davies C, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, et al.
Front Oncol
. 2023 Feb;
12:1060864.
PMID: 36727071
Background: Docetaxel improves overall survival (OS) in castration-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired resistance. There remains...
4.
Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, et al.
Front Cell Dev Biol
. 2021 Jan;
8:602493.
PMID: 33490068
Castration-resistant prostate cancer (CRPC) is the major cause of death from prostate cancer. Biomarkers to improve early detection and prediction of CRPC especially using non-invasive liquid biopsies could improve outcomes....
5.
Scandura G, Wagner T, Beltran L, Alifrangis C, Shamash J, Berney D
Mod Pathol
. 2020 Dec;
34(4):834-841.
PMID: 33319858
Pathological risk factors for metastatic disease in patients with testicular non-seminomatous germ cell tumors are debated. The tumor-node-metastasis (TNM) classification eighth edition for testicular cancers includes divergent versions, by the...
6.
Wagner T, Scandura G, Roe A, Beltran L, Shamash J, Alfrangis C, et al.
Mod Pathol
. 2019 Nov;
33(4):713-721.
PMID: 31695156
In 2016, the World Health Organization classification system of testicular tumors included the new entity prepubertal-type teratoma based on its morphological and molecular profile, and the realization that these tumors...
7.
Scandura G, Wagner T, Beltran L, Alifrangis C, Shamash J, Berney D
Hum Pathol
. 2019 Nov;
94:16-22.
PMID: 31666197
Management of clinical stage (CS) 1 testicular seminoma is controversial. Treatment choice is based on a number of pathological risk factors. However, they have been inconsistently associated with risk of...
8.
Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, et al.
J Urol
. 2019 Oct;
203(1):81-82.
PMID: 31580196
No abstract available.
9.
Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, et al.
J Urol
. 2019 Aug;
203(1):73-82.
PMID: 31389764
Purpose: Prostate specific antigen testing results in unnecessary biopsy and over diagnosis with consequent overtreatment. Tissue biopsy is an invasive procedure associated with significant morbidity. More accurate noninvasive or minimally...
10.
Yeste-Velasco M, Guo T, Mao X, Stankiewicz E, Scandura G, Li H, et al.
Am J Cancer Res
. 2019 Jun;
9(5):855-871.
PMID: 31218098
Testicular germ cell tumors (TGCTs) are the commonest tumors in young men. With the advancement of chemotherapies, most TGCTs are successfully cured, even when diagnosed at an advanced and metastatic...